ENYO Pharma, a biopharmaceutical company focused on developing treatments for viral infections, has announced that it has received a grant of €2.5m.
ENYO Pharma’s MIMESIS project applied for the June 2016 funding cut-off under the topic ‘Dedicated support to biotechnology SMEs closing the gap from lab to market’.
After a feasibility Phase that generated ENYO’s internal drug development programme on an autophagy target, MIMESIS will be expanded to an industrialised scale to accelerate the discovery of new therapeutic targets and innovative new chemical entities against infectious diseases and cancer.
Dr Eric Meldrum, ENYO Pharma’s chief scientific officer, said: “We are very honoured to receive the recognition from the Horizon 2020 jury in what was a highly competitive process.
“MIMESIS represents a real paradigm shift in the development of new innovative drugs for pathologies where the medical need is immense. This financing will enable us to screen our library of original peptides and small molecules on hundreds of intracellular human targets previously untapped by the pharmaceutical industry.”
For the project ENYO Pharma has designed a proprietary library of 10,000 small molecules to modulate host cell biology. This library of developable chemical templates will be screened in phenotypic assays for inhibitors of the replication cycle of several viruses and a mycobacterium. As this library is designed to modulate host cell biology, it will also be screened for inducers of Immunogenic Cell Death (ICD) in tumours.
Upon completion of MIMESIS, ENYO Pharma is to further optimise its best chemical series.